Thermo Fisher Scientific Inc (TMO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $259.44B
Last updated: Nov 17, 2026 at 11:06 AM ET
Thermo Fisher Scientific Inc (TMO) Financials: Revenue, Profit and Cash Flow
Thermo Fisher Scientific reported revenue of $44.56B for the fiscal year ended Dec 31, 2025, up 3.9% from the year before. That year, net income was $6.72B with a net margin of 15.1%, operating cash flow was $7.82B and free cash flow was $6.29B. The quarter ended Sep 30, 2026 had revenue of $12.14B and net income of $1.73B.
Revenue and Margins
The operating margin was 17.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $18.27B, a compound annual rate of 10.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44.56B | +3.9% | 40.9% | 17.4% | 15.1% |
| Dec 2024 | $42.88B | +0.1% | 41.3% | 17.1% | 14.8% |
| Dec 2023 | $42.86B | -4.6% | 39.9% | 16.0% | 13.9% |
| Dec 2022 | $44.91B | +14.5% | 42.2% | 18.7% | 15.5% |
| Dec 2021 | $39.21B | +21.7% | 50.1% | 25.6% | 19.7% |
| Dec 2020 | $32.22B | +26.1% | 49.7% | 24.2% | 19.8% |
| Dec 2019 | $25.54B | +4.9% | 44.4% | 18.0% | 14.5% |
| Dec 2018 | $24.36B | +16.4% | 44.6% | 15.5% | 12.1% |
| Dec 2017 | $20.92B | +14.5% | 45.2% | 14.2% | 10.6% |
| Dec 2016 | $18.27B | N/A | 45.8% | 13.5% | 11.1% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 6.0% from the year before. In the quarter ended Sep 2026, net income rose 6.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | $20.92B | $18.27B |
| Cost of revenue | $26.32B | $25.18B | $25.76B | $25.94B | $19.57B | $16.21B | $14.21B | $13.50B | $11.47B | $9.90B |
| Gross profit | $18.24B | $17.70B | $17.10B | $18.97B | $19.64B | $16.00B | $11.33B | $10.86B | $9.45B | $8.37B |
| Research and development | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1.00B | $967.00M | $887.00M | $754.00M |
| Operating income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | $2.96B | $2.46B |
| Net income | $6.72B | $6.34B | $5.96B | $6.96B | $7.73B | $6.38B | $3.70B | $2.94B | $2.23B | $2.02B |
| EBITDA | $10.51B | $10.46B | $10.20B | $11.67B | $11.93B | $10.04B | $6.80B | $6.06B | $4.97B | $3.78B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.14B | $11.99B | $11.01B | $12.21B | $11.12B | $10.86B | $10.36B | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B |
| Gross profit | $5.13B | $4.88B | $4.43B | $5.01B | $4.58B | $4.41B | $4.24B | $4.82B | $4.33B | $4.35B | $4.21B | $4.39B |
| Operating income | $2.26B | $2.09B | $1.86B | $2.25B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B | $1.82B | $1.66B | $1.85B |
| Net income | $1.73B | $1.74B | $1.66B | $1.97B | $1.62B | $1.62B | $1.51B | $1.82B | $1.63B | $1.55B | $1.33B | $1.61B |
Balance Sheet
As of Dec 2025, total debt of $39.38B exceeded cash and equivalents by $29.53B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | $56.67B | $45.91B |
| Current assets | $28.71B | $22.14B | $24.59B | $25.23B | $20.11B | $21.96B | $11.89B | $10.63B | $9.42B | $7.02B |
| Cash and equivalents | $9.85B | $4.01B | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B | $2.10B | $1.33B | $786.00M |
| Total liabilities | $56.81B | $47.65B | $51.88B | $53.01B | $54.15B | $34.53B | $28.71B | $28.65B | $31.26B | $24.37B |
| Short-term debt | $3.53B | $2.21B | $3.61B | $5.58B | $2.54B | $2.63B | $676.00M | $1.27B | $2.13B | $1.25B |
| Long-term debt | $35.85B | $29.06B | $31.31B | $28.91B | $32.33B | $19.11B | $17.08B | $17.72B | $18.87B | $15.37B |
| Shareholder equity | $53.41B | $49.58B | $46.73B | $43.98B | $40.79B | $34.51B | $29.68B | $27.59B | $25.41B | $21.54B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $114.23B | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B |
| Total liabilities | $59.34B | $60.37B | $61.22B | $56.81B | $51.87B | $50.63B | $49.56B | $47.65B | $51.26B | $50.96B | $51.47B | $51.88B |
| Cash and equivalents | $5.46B | $4.06B | $3.25B | $9.86B | $1.98B | $4.58B | $4.13B | $4.02B | $4.64B | $7.07B | $5.50B | $8.08B |
| Shareholder equity | $54.76B | $52.68B | $51.93B | $53.41B | $51.02B | $50.51B | $49.39B | $49.58B | $48.99B | $47.43B | $45.52B | $46.73B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 80.4% of operating cash flow. Dividends and share repurchases together came to 57.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B | $4.00B | $3.26B |
| Capital expenditures | $1.52B | $1.40B | $1.48B | $2.24B | $2.52B | $1.47B | $926.00M | $758.00M | $508.00M | $444.00M |
| Free cash flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | $3.50B | $2.81B |
| Dividends paid | $636.00M | $583.00M | $523.00M | $455.00M | $395.00M | $337.00M | $297.00M | $266.00M | $237.00M | $238.00M |
| Share repurchases | $3.00B | $4.00B | $3.00B | $3.00B | $2.00B | $1.50B | $1.50B | $500.00M | $750.00M | $1.25B |
| Investing cash flow | -$4.05B | -$5.84B | -$5.14B | -$2.16B | -$21.93B | -$1.51B | -$1.49B | -$1.25B | -$7.73B | -$5.52B |
| Financing cash flow | $1.80B | -$6.79B | -$3.62B | -$2.81B | $6.58B | $959.00M | -$3.12B | -$2.24B | $3.85B | $2.76B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.55B | $2.13B | $1.19B | $3.46B | $2.24B | $1.40B | $723.00M | $3.29B | $2.17B | $1.96B | $1.25B | $3.72B |
| Capital expenditures | $437.00M | $450.00M | $376.00M | $465.00M | $404.00M | $294.00M | $362.00M | $480.00M | $272.00M | $301.00M | $347.00M | $405.00M |
| Free cash flow | $2.11B | $1.68B | $816.00M | $2.99B | $1.83B | $1.10B | $361.00M | $2.81B | $1.89B | $1.66B | $904.00M | $3.32B |
Frequently Asked Questions About TMO
What is Thermo Fisher Scientific's annual revenue?
Thermo Fisher Scientific reported revenue of $44.56B for the fiscal year ended Dec 31, 2025.
How fast is Thermo Fisher Scientific's revenue growing?
Revenue was up 3.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.
Is Thermo Fisher Scientific profitable?
Yes. Thermo Fisher Scientific reported net income of $6.72B for the fiscal year ended Dec 31, 2025, with a net margin of 15.1%.
How much free cash flow does TMO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $7.82B minus capital expenditures of $1.52B produced free cash flow of $6.29B.
How much debt does Thermo Fisher Scientific have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $35.85B, short-term debt of $3.53B and cash and equivalents of $9.85B.
TMO pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts